Renaissance Technologies
BCTX

Renaissance Technologies’s Briacell Therapeutics BCTX Stock Holding History

Renaissance Technologies’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100
Closed -$17.1K – 3532
2024
Q2 		$17.1K Buy
100
+19
+23% +$5.38K ﹤0.01% 3395
2024
Q1 		$35K Buy
81
+8
+11% +$4.41K ﹤0.01% 3534
2023
Q4 		$64K Buy
73
+5
+7% +$3.59K ﹤0.01% 3405
2023
Q3 		$64K Buy
+68
New +$66.6K ﹤0.01% 3347

Other funds holding BCTX

Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
OBWG
Onyx Bridge Wealth Group Tarrytown, New York $1.11B AUM 24.65% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
STA
Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Renaissance Technologies's BCTX Position: Q3 2024 in Review

Renaissance Technologies sold out of Briacell Therapeutics (BCTX) in Q3 2024, closing a stake of 100 shares — an estimated $17.1K sold.

Renaissance Technologies first reported a position in BCTX in Q3 2023 and held it in 4 quarters. The position peaked at $64K in Q4 2023. 21 funds tracked by Wall St. Rank hold BCTX as of Q3 2024.

  • Renaissance Technologies reported no remaining Briacell Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Renaissance Technologies sold 100 Briacell Therapeutics shares in Q3 2024, an estimated $17.1K.
  • Renaissance Technologies first reported a position in Briacell Therapeutics in Q3 2023 and held it in 4 quarters.
  • Renaissance Technologies's Briacell Therapeutics position peaked at $64K in Q4 2023.
  • 21 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q3 2024.

Based on Renaissance Technologies's 13F filing for Q3 2024, filed 13 Nov 2024.